BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45th Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025.
Presentation Details
Format: Fireside Chat
Date: Tuesday, August 12, 2025
Time: 2:00 PM ET
Webcast Link: https://wsw.com/webcast/canaccord108/crvo/2537558
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-430-7579
| Last Trade: | US$10.12 |
| Daily Change: | -0.07 -0.69 |
| Daily Volume: | 120,309 |
| Market Cap: | US$88.040M |
August 11, 2025 July 24, 2025 July 08, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
